Helicobacter Pylori Infections Market Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Phathom Pharmaceuticals

April 24 17:32 2023
 Helicobacter Pylori Infections Market Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Phathom Pharmaceuticals
DelveInsight Business Research
DelveInsight’s ‘H. pylori Infection – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the H. pylori Infection, historical and forecasted epidemiology as well as the H. pylori Infection market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

DelveInsight’s ‘H. pylori Infection – Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the H. pylori Infection, historical and forecasted epidemiology as well as the H. pylori Infection market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

Helicobacter Pylori Infections Market Overview

Helicobacter pylori  (H. pylori) infection is caused by bacteria, which in turn, causes stomach infection. These infections cause stomach and duodenum changes, leading to gastritis and stomach cancer. Consuming contaminated food and water (with fecal matter) spreads H. pylori infection. Patients harboring the bacteria are asymptomatic with abdominal pain, nausea, vomiting, and dyspepsia developing only after gastritis and peptic ulcer disease have set in. H. pylori is the most important cause for chronic or atrophic gastritis, peptic ulcer, gastric lymphoma, and gastric carcinoma; however, these complications are less often seen in children and adolescents than adults. H. pylori infection is usually acquired in early childhood and persists without treatment. Four important components lead to the formation of clinical diseases such as gastritis and ulcer in H. pylori infection. First, the urease activity of H. pylori plays an important role in countering the stomach’s acidic environment. Second, the flagella-mediated motility helps H. pylori bacterium move toward the host gastric epithelial cells. This is followed by the bacterial adhesins interacting with the host cell receptors, leading to successful colonization and persistent infection. Finally, many effector proteins/toxins include cytotoxin-associated gene A (Cag A) and vacuolating cytotoxin A (VacA) released by H. pylori, leading to host tissue damage.

 

Learn more about the Helicobacter Pylori Infections market @ Helicobacter Pylori Infections  Market Landscape

 

Helicobacter Pylori Infections Epidemiological Segmentation 

  • Helicobacter Pylori Infections incident cases

  • Helicobacter Pylori Infections treated cases

  • Helicobacter Pylori Infections diagnosed cases

  • Helicobacter Pylori Infections prevalent cases 

Helicobacter Pylori Infections Market Outlook 

With no single accurate diagnostic tool or method, the current diagnosis depends on both invasive and noninvasive methods. The treatment regime has seen many changes, with H. pylori designated as a Class I carcinogen by WHO and a Qualifying Pathogen under the US FDA GAIN Act. The first effective therapy for H. pylori was introduced in the 1980s; since then, there have been major changes. The current treatment regime for H. pylori is therapeutic and not prophylactic; the goal is to eradicate the bacteria, as eradication alone is paramount for healing associated peptic ulcers and preventing relapses. But the growing prevalence of antibiotic resistance has made it a global challenge.Most treatment guidelines recommend triple therapies, a combination of antibiotics with either antisecretories or PPIs or other acid-regulating agents, as the first line of treatment for eradicating H. pylori. Monotherapies prove ineffective as stomach acidity reduces the efficacy of antibiotics. Moreover, increasing antibiotic resistance has added to the troubles with only a few antibiotics active against H. pylori, including clarithromycin, amoxicillin, metronidazole, fluoroquinolone (levofloxacin, norfloxacin), tetracycline, and rifabutin.

Key Companies in the Helicobacter Pylori Infections Market Include

  • Phathom Pharmaceuticals

  • Redhill Biopharma

  • Takeda Pharmaceutical

  • Otsuka Pharmaceutical

  • Juvisé Pharmaceuticals

  • AbbVie

  • Cumberland Pharmaceuticals

  • Pernix Therapeutics

  • Eisai Co

And many others

Helicobacter Pylori Infections Therapies Covered and Analyzed in the Report Market Include:

  • VOQUEZNA TRIPLE PAK 

  • TALICIA (RHB-105)

  • BAS 118, SCG321,

  • R435/R529 

  • Lansoprazole

  • Esomeprazole

  • OBMT

  • Tegoprazan

  • GT08

And many others 

 

Learn more about the Helicobacter Pylori Infections Market, Key Companies, and Emerging Therapies 

Table of Contents

  1. Key Insights 

  2. Helicobacter Pylori Infections   Report Introduction 

  3. Executive Summary of the Helicobacter Pylori Infections Market  

  4. Helicobacter Pylori Infections Disease Background and Overview

  5. Helicobacter Pylori Infections Epidemiology and patient population

  6. Helicobacter Pylori Infections Market Emerging Therapies

  7. Helicobacter Pylori Infections Market Drivers 

  8. Helicobacter Pylori Infections Market Barriers 

  9. Market Access and Reimbursement of Therapies

  10. Appendix

  11. Report Methodology

  12. DelveInsight Capabilities

  13. Disclaimer

  14. About DelveInsight

Learn more about the detailed report offerings @ Helicobacter Pylori Infections  Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

  Categories: